Granules India Limited has announced robust financial results for the first quarter of FY27. The company reported a significant increase in Revenue, up 22% YoY to ₹14,768 Mn. Profit After Tax (PAT) saw a substantial surge of 60% YoY to ₹1,800 Mn, while EBITDA grew by 37% YoY to ₹3,389 Mn. The company also highlighted advancements in its Complex Gx portfolio and strategic initiatives aimed at sustainable growth.
Granules India Reports Strong Q1 FY27 Performance
Granules India Limited has unveiled its financial results for the first quarter of the Fiscal Year 2027 (Q1 FY27), showcasing significant year-over-year growth across key financial metrics. The company’s strategic focus on its Complex Gx portfolio and operational efficiencies has contributed to this strong performance.
Key Financial Highlights
Revenue for the quarter reached ₹14,768 Mn, marking a substantial 22% increase compared to the same period last year. Profit After Tax (PAT) demonstrated exceptional growth, rising by 60% YoY to ₹1,800 Mn. Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) also saw robust expansion, growing by 37% YoY to ₹3,389 Mn. The company’s EBITDA margin improved to 22.9%.
Portfolio and Business Advancements
The presentation highlighted the increasing contribution of the Complex Gx mix to the company’s Finished Dosages (FD) portfolio, now accounting for 50%. This strategic shift has positively impacted gross margins, lifting them to 65.6%. Furthermore, the company reported an improvement in its Net Debt/EBITDA ratio to 0.07x and a Return on Capital Employed (ROCE) of 18.0%. Investments in R&D, amounting to ₹880 Mn (6.0% of sales), are focused on seeding a high-value pipeline for future growth.
Market Position and Future Outlook
Granules India continues to strengthen its market leadership, particularly in the US products portfolio, ranking #1 in 10 out of 35 products and Top-3 in 18 products. The company also reported significant progress in its R&D pipeline, with 5 FD and 4 API filings in Q1FY27. Future growth is expected to be driven by its diversified revenue streams, complex generics, and geographic expansion.
Sustainability and Compliance
The company also touched upon its commitment to sustainability and quality compliance, noting the successful completion of regulatory audits and certifications. Efforts are ongoing to enhance manufacturing capabilities and digital transformation initiatives to ensure robust quality operations.
Source: BSE
